PDS Biotechnology Corpora... (PDSB)
PDS Biotechnology Corporation (PDSB) Stock Price, Analysis & Data
| Bid | 0.17 |
| Market Cap | 12.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.67M |
| Beta | n/a |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.57 |
| P/B (ttm) | 1.36 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 0.3 |
| Volume | 1,747,296 |
| Avg. Volume (20D) | 1,219,498 |
| Open | 0.23 |
| Previous Close | 0.23 |
| Day's Range | 0.23 - 0.24 |
| 52-Week Range | 0.22 - 1.55 |
| Analyst | Strong Buy |
| Price Target | 5.75 (2400.00%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an inves...
Financial Performance
In 2025, PDS Biotechnology's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -34.5M, a decrease of -8.28%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for PDSB stock is "Strong Buy". The 12-month stock price forecast is 5.75, which is upside of 2400% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
